Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults.

导出 OA

翻译打印收藏纠错

第一作者： Karen,Tashima

第一单位： The Miriam Hospital, Providence, RI, USA.

作者： Karen,Tashima ^[1] ; Gordon,Crofoot ^[2] ; Frank L,Tomaka ^[3] ; Thomas N,Kakuda ^[3] ; Anne,Brochot ^[4] ; Simon,Vanveggel ^[5] ; Magda,Opsomer ^[5] ; William,Garner ^[6] ; Nicolas,Margot ^[6] ; Joseph M,Custodio ^[6] ; Marshall W,Fordyce ^[6] ; Javier,Szwarcberg ^[6]

作者单位： The Miriam Hospital, Providence, RI, USA. ^[1] Gordon Crofoot Research, Houston, TX, USA. ^[2] Janssen Research & Development, LLC, Titusville, FL, USA. ^[3] Janssen Research & Development, LLC, Beerse, Belgium. ^[4] Janssen Infectious Diseases BVBA, Beerse, Belgium. ^[5] Gilead Sciences, Foster City, CA, USA. ^[6]

DOI 10.7448/IAS.17.4.19772

PMID 25397516

发布时间 2018-10-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览10

Journal of the International AIDS Society

2014年17卷4 Suppl 3期

19772页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults.

Journal of the International AIDS Society

相似文献

Journal of the International AIDS Society

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults.

Journal of the International AIDS Society

相似文献

Journal of the International AIDS Society

相关期刊

检索历史清除